Clinical TrialsCelldex’s Barzolvolimab Fails to Deliver Clinical Benefit in Atopic D... Celldex’s Barzolvolimab Fails to Deliver Clinical Benefit in Atopic D... Read Post »
Clinical TrialsBioVersys Reports Promising Phase 2a Results for Alpibectir in TB BioVersys Reports Promising Phase 2a Results for Alpibectir in TB Read Post »
Clinical TrialsRevMed Reports Promising Phase 1/2 Results for Daraxonrasib Plus GnP RevMed Reports Promising Phase 1/2 Results for Daraxonrasib Plus GnP Read Post »
Clinical TrialsBiohaven’s BHV-1530 Delivers Responses in Advanced Cancers Biohaven’s BHV-1530 Delivers Responses in Advanced Cancers Read Post »
Clinical TrialsImmutep Reports 81.1% DFS with Efti Combination in Sarcoma Immutep Reports 81.1% DFS with Efti Combination in Sarcoma Read Post »
Clinical TrialsLilly’s Mevidalen Misses Primary Endpoint in Alzheimer’s Trial Lilly’s Mevidalen Misses Primary Endpoint in Alzheimer’s Trial Read Post »
Clinical TrialsEisai and Biogen Report 76% Lower Dementia Progression with LEQEMBI Eisai and Biogen Report 76% Lower Dementia Progression with LEQEMBI Read Post »
Clinical TrialsBMS Reports First Phase 3 KarXT Findings in Alzheimer’s Psychosis BMS Reports First Phase 3 KarXT Findings in Alzheimer’s Psychosis Read Post »
Clinical TrialsNovo Nordisk’s Semaglutide Cuts BMI 13.5% in Children Under 12 Novo Nordisk’s Semaglutide Cuts BMI 13.5% in Children Under 12 Read Post »
Clinical TrialsAbbVie Fails to Meet Primary Endpoint in Upadacitinib Takayasu Trial AbbVie Fails to Meet Primary Endpoint in Upadacitinib Takayasu Trial Read Post »
Clinical TrialsBiogen’s Diranersen Shows Sustained Clinical Effects in AlzheimerR... Biogen’s Diranersen Shows Sustained Clinical Effects in AlzheimerR... Read Post »
Clinical TrialsPriavoid’s PRI-002 Misses Phase 2 Efficacy Goal in Alzheimer’s ... Priavoid’s PRI-002 Misses Phase 2 Efficacy Goal in Alzheimer’s ... Read Post »
Clinical TrialsCG Oncology’s Cretostimogene Cuts NMIBC Recurrence Risk by 68% CG Oncology’s Cretostimogene Cuts NMIBC Recurrence Risk by 68% Read Post »
Clinical TrialsSELLAS Galinpepimut-S Meets Phase 3 REGAL Trial Endpoint in AML SELLAS Galinpepimut-S Meets Phase 3 REGAL Trial Endpoint in AML Read Post »
Clinical TrialsOncoinvent Reports No Drug-Related Serious Adverse Events With Radspherin Oncoinvent Reports No Drug-Related Serious Adverse Events With Radspherin Read Post »
Clinical TrialsAriBio Reports Mixed Phase 3 Results for Alzheimer’s Drug AriBio Reports Mixed Phase 3 Results for Alzheimer’s Drug Read Post »
Clinical TrialsUniquity’s Solrikitug Meets Both Phase 2 Endpoints in EoE Uniquity’s Solrikitug Meets Both Phase 2 Endpoints in EoE Read Post »
Clinical TrialsEisai and Biogen Report Long-Term Lecanemab Outcomes in Alzheimer’s Eisai and Biogen Report Long-Term Lecanemab Outcomes in Alzheimer’s Read Post »
Clinical TrialsHelus’s HLP003 Delivers Positive Results in MDD Helus’s HLP003 Delivers Positive Results in MDD Read Post »
Clinical TrialsHengrui Reports 17.7% Weight Loss With Ribupatide in GEMINI-1 Trial Hengrui Reports 17.7% Weight Loss With Ribupatide in GEMINI-1 Trial Read Post »
Clinical TrialsEli Lilly Reports 18.5% BMI Reduction With Tirzepatide in Adolescents Eli Lilly Reports 18.5% BMI Reduction With Tirzepatide in Adolescents Read Post »
Clinical TrialsSyntis Bio Reports 28-Day Weight-Loss Results for Oral SYNT-101 Syntis Bio Reports 28-Day Weight-Loss Results for Oral SYNT-101 Read Post »
Clinical Trials Disease & DrugsNovo Nordisk Reports New CagriSema Results Across REDEFINE Trials Novo Nordisk Reports New CagriSema Results Across REDEFINE Trials Read Post »
Clinical TrialsAlpha Tau Reports Strong Early Responses in Glioblastoma Trial Alpha Tau Reports Strong Early Responses in Glioblastoma Trial Read Post »
Clinical TrialsRoche Secures Positive CHMP Recommendation for Obinutuzumab in SLE Roche Secures Positive CHMP Recommendation for Obinutuzumab in SLE Read Post »
Clinical TrialsMerck Gains EU CHMP Backing for Belzutifan in Advanced RCC Merck Gains EU CHMP Backing for Belzutifan in Advanced RCC Read Post »
Clinical TrialsZai Lab’s ZL-1503 Sustains Atopic Dermatitis Biomarker Suppression Th... Zai Lab’s ZL-1503 Sustains Atopic Dermatitis Biomarker Suppression Th... Read Post »
Clinical TrialsBioCryst Reports Reduced Healthcare Utilization Across ORLADEYO Studies BioCryst Reports Reduced Healthcare Utilization Across ORLADEYO Studies Read Post »
Clinical TrialsOrganon Reports Consistent Skin and Itch Improvements With VTAMA Organon Reports Consistent Skin and Itch Improvements With VTAMA Read Post »
Clinical TrialsRegeneron’s Baloncibart Delivers Sustained Heart Rate Benefits in POTS Regeneron’s Baloncibart Delivers Sustained Heart Rate Benefits in POTS Read Post »
Clinical TrialsIonis Reports Long-Term Attack Reduction with DAWNZERA in HAE Ionis Reports Long-Term Attack Reduction with DAWNZERA in HAE Read Post »
Clinical TrialsPharvaris Adds Long-Term HAE Prophylaxis and On-Demand Data for Deucrictiba... Pharvaris Adds Long-Term HAE Prophylaxis and On-Demand Data for Deucrictiba... Read Post »
Clinical TrialsCuraSen’s CuraAX Improves Standing Blood Pressure in Phase 2a CuraSen’s CuraAX Improves Standing Blood Pressure in Phase 2a Read Post »
Clinical TrialsLilly’s Taltz-Zepbound Combination Delivers 43.7% ACR50 Response Lilly’s Taltz-Zepbound Combination Delivers 43.7% ACR50 Response Read Post »
Clinical TrialsVasa Reports NT-proBNP Reduction With VS-041 in HFpEF Trial Vasa Reports NT-proBNP Reduction With VS-041 in HFpEF Trial Read Post »
Clinical TrialsBeeline Reports Positive Phase 2 Results for Afimetoran in SLE Beeline Reports Positive Phase 2 Results for Afimetoran in SLE Read Post »
Clinical TrialsRegeneron’s CIDEB siRNA Sustains 80% Liver Fat Reduction Regeneron’s CIDEB siRNA Sustains 80% Liver Fat Reduction Read Post »
Clinical TrialsAmgen’s Dazodalibep Meets Phase 3 Goal in Sjögren’s Disease Amgen’s Dazodalibep Meets Phase 3 Goal in Sjögren’s Disease Read Post »
Clinical TrialsNovartis Reports Two-Year Ianalumab Results in Sjögren’s Disease Novartis Reports Two-Year Ianalumab Results in Sjögren’s Disease Read Post »
Clinical TrialsBeam Reports Positive BEACON Results for Risto-cel in SCD Beam Reports Positive BEACON Results for Risto-cel in SCD Read Post »
Clinical TrialsAlnylam Highlights 5-Year Cardiovascular Benefits of Vutrisiran Alnylam Highlights 5-Year Cardiovascular Benefits of Vutrisiran Read Post »
Clinical TrialsMerck Reports Positive Phase 2b Results for Efinopegdutide in MASH Merck Reports Positive Phase 2b Results for Efinopegdutide in MASH Read Post »
Clinical TrialsBoehringer Reports Positive Phase III CV Safety Results for Survodutide Boehringer Reports Positive Phase III CV Safety Results for Survodutide Read Post »
Clinical TrialsLilly’s Foundayo Improves OSA Severity in PAP and Non-PAP Users Lilly’s Foundayo Improves OSA Severity in PAP and Non-PAP Users Read Post »
Clinical TrialsGilead Reports Higher PrEP Persistence with Lenacapavir in PURPOSE 5 Gilead Reports Higher PrEP Persistence with Lenacapavir in PURPOSE 5 Read Post »
Clinical Trials Disease & DrugsUCB and Biogen Report Positive Lupus Findings for Dapirolizumab UCB and Biogen Report Positive Lupus Findings for Dapirolizumab Read Post »
Clinical TrialsNovo Nordisk Reports Improved Fibrosis Markers With Wegovy in MASH Novo Nordisk Reports Improved Fibrosis Markers With Wegovy in MASH Read Post »
Clinical Trialsargenx Meets Phase III Endpoint With Efgartigimod in Autoimmune Myositis argenx Meets Phase III Endpoint With Efgartigimod in Autoimmune Myositis Read Post »
Clinical TrialsCullinan Reports 4 Renal Responses With Velinotamig in Lupus Study Cullinan Reports 4 Renal Responses With Velinotamig in Lupus Study Read Post »
Clinical TrialsAulos Reports 9.1-Month PFS with Imneskibart in Melanoma Aulos Reports 9.1-Month PFS with Imneskibart in Melanoma Read Post »